이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CAR-MA(CAR-Multicenter Analysis): B-ALL이 있는 소아 및 청년의 CAR T 세포 결과 및 관련 독성을 특성화하기 위한 후향적 연구

2026년 10월 23일 업데이트: National Cancer Institute (NCI)

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.

To evaluate the response of extramedullary disease following CAR T-cell therapy.

To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.

연구 개요

상세 설명

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

  • To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

  • To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
  • To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
  • To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
  • To evaluate the response of extramedullary disease following CAR T-cell therapy.
  • To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
  • To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
  • To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
  • To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
  • To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

연구 유형

관찰

등록 (실제)

57

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Cancer Institute (NCI)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

3년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.

설명

  • Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: RETROSPECTIVE

코호트 및 개입

그룹/코호트
1

Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Response free survival (completed)
기간: 6 months

To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab.

6 months
Outcome evaluation
기간: 12 months

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Complete Response Rate (completed)
기간: 12 months

To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Relapse Rate (completed)
기간: 12 months

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Response free survival (completed)
기간: 12 months

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Minimal Residual Disease detection (completed)
기간: 12 months

To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Impact of immunotherapies on CAR outcomes
기간: 12 months

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes

12 months
Cytopenias after CAR
기간: 12 months

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes

12 months
Response of extramedullary disease
기간: 12 months

To evlauate the response of extramedullary disease following CAR T cell therapy

12 months
Frequency of malignant neoplasms
기간: 12 months

To evaluate the response of extramedullary disease following CAR T cell therapy

12 months
Response, survival and toxicities in subpopulations
기간: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

12 months
Impact of next generation sequencing MRD and duration of B cell aplasia
기간: 12 months

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

12 months
Frequency of infections
기간: 12 months

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

12 months
Response, survival and toxicities after CAR
기간: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy)

12 months
Compare toxicities and outcomes across CAR constructs
기간: 12 months

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.)

12 months
Impact of CAR on other health-related outcomes
기간: 12 months

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes

12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Sara K Silbert, M.D., National Cancer Institute (NCI)

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 10월 14일

기본 완료 (실제)

2024년 10월 29일

연구 완료 (실제)

2024년 10월 29일

연구 등록 날짜

최초 제출

2022년 6월 29일

QC 기준을 충족하는 최초 제출

2022년 6월 29일

처음 게시됨 (실제)

2022년 6월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 26일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 23일

마지막으로 확인됨

2026년 10월 22일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD 공유 기간

Clinical data available during the study and indefinitely.

IPD 공유 액세스 기준

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다